157117-83-4 Usage
Uses
Used in Pharmaceutical Industry:
2-[(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]benzonitrile is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows it to be incorporated into the design and development of new drugs, potentially leading to innovative treatments for a range of medical conditions.
Used in Organic Chemistry Research:
2-[(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]benzonitrile is also utilized in the field of organic chemistry and chemical research. Its properties make it a valuable tool for studying reaction mechanisms, exploring new synthetic pathways, and developing novel organic compounds with potential applications in various industries.
Used in Material Science:
Due to its unique structure and properties, 2-[(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]benzonitrile has the potential to be used in the development of new materials. Its incorporation into material formulations could lead to the creation of advanced materials with improved properties, such as enhanced stability, reactivity, or selectivity, depending on the specific application.
Check Digit Verification of cas no
The CAS Registry Mumber 157117-83-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,7,1,1 and 7 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 157117-83:
(8*1)+(7*5)+(6*7)+(5*1)+(4*1)+(3*7)+(2*8)+(1*3)=134
134 % 10 = 4
So 157117-83-4 is a valid CAS Registry Number.
157117-83-4Relevant academic research and scientific papers
COMPOSITIONS FOR PROMOTING READTHROUGH OF PREMATURE TERMINATION CODONS, AND METHODS OF USING THE SAME
-
Page/Page column 213; 214; 215; 216; 217; 218, (2017/04/11)
Disclosed are compounds of general formula (I) that promote readthrough of a premature termination codon (PTC) of an RNA molecule in a translation system, and their use, alone or in combination with other compounds, such as aminoglycoside, to treat diseases or disorders ameliorated by modulation of a premature termination codon (PTC) of an RNA molecule in a translation system. The disorder or disease may be Dystrophic epidermolysis bullosa, Batten disease, Duchenne muscular dystrophy, cancer, and spinal muscular atrophy. Ar-L-B (I)
Imidazole derivatives as PDE10A enzyme inhibitors
-
Page/Page column 9, (2012/06/01)
This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The pr
Benzodiazepines and isoindoles by acylation of amidines
Lessel
, p. 812 - 816 (2007/10/02)
The reaction of amidines with difunctional electrophiles represents a simple access to N-heterocycles as anellated 2,4-benzodiazepines and isoindoles. A new model to describe the reactivity of molecules quantitatively has been elaborated and used to explain the formation of the heterocyclic products.
